Innoviva (INVA) EPS (Basic) Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.06% |
| Dec 31, 2025 | -19.01% |
| Sep 30, 2025 | 35.94% |
| Jun 30, 2025 | 5.85% |
| Mar 31, 2025 | -25.70% |
| Dec 31, 2024 | -18.87% |
| Sep 30, 2024 | -44.79% |
| Jun 30, 2024 | -28.37% |
| Mar 31, 2024 | 11.94% |
| Dec 31, 2023 | -15.31% |
| Sep 30, 2023 | 21.80% |
| Jun 30, 2023 | -48.27% |
| Mar 31, 2023 | 11.95% |
| Dec 31, 2022 | -17.81% |
| Sep 30, 2022 | 76.89% |
| Jun 30, 2022 | -50.31% |
| Mar 31, 2022 | 7.53% |
| Dec 31, 2021 | -18.20% |
| Sep 30, 2021 | 49.34% |
| Jun 30, 2021 | 50.69% |
| Mar 31, 2021 | 87.62% |
| Dec 31, 2020 | 67.67% |
| Sep 30, 2020 | 55.18% |
| Jun 30, 2020 | 66.66% |
| Mar 31, 2020 | 55.94% |
| Dec 31, 2019 | 39.14% |
| Sep 30, 2019 | 32.30% |
| Jun 30, 2019 | 32.32% |
| Mar 31, 2019 | 33.24% |
| Dec 31, 2018 | 50.32% |
| Sep 30, 2018 | 48.50% |
| Jun 30, 2018 | 28.17% |
| Mar 31, 2018 | 35.91% |
| Dec 31, 2017 | 29.33% |
| Sep 30, 2017 | 21.01% |
| Jun 30, 2017 | 22.74% |
| Mar 31, 2017 | -30.82% |
| Dec 31, 2016 | 20.43% |
| Sep 30, 2016 | 18.92% |
| Jun 30, 2016 | 19.33% |
| Mar 31, 2016 | 16.47% |
| Dec 31, 2015 | 16.65% |
| Sep 30, 2015 | 32.71% |
| Jun 30, 2015 | 24.21% |